Progress in TB drug development and what is still needed
- 19 February 2003
- journal article
- review article
- Published by Elsevier in Tuberculosis
- Vol. 83 (1-3) , 201-207
- https://doi.org/10.1016/s1472-9792(02)00076-8
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- In Situ Detection of Mycobacterium tuberculosis Transcripts in Human Lung Granulomas Reveals Differential Gene Expression in Necrotic LesionsInfection and Immunity, 2002
- Characterization of a Mycobacterium tuberculosis H37Rv transposon library reveals insertions in 351 ORFs and mutants with altered virulence b bThe precise locations of all of the insertions examined in this study can be found as supplementary data in Microbiology Online (http://mic.sgmjournals.org).Microbiology, 2002
- Whole-Genome Comparison ofMycobacterium tuberculosisClinical and Laboratory StrainsJournal of Bacteriology, 2002
- Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trialThe Lancet, 2002
- Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profilingMolecular Microbiology, 2002
- Airways delivery of rifampicin microparticles for the treatment of tuberculosisJournal of Antimicrobial Chemotherapy, 2001
- Massive gene decay in the leprosy bacillusNature, 2001
- A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosisNature, 2000
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- Thiolactomycin, a new antibiotic. I. Taxonomy of the producing organism, fermentation and biological properties.The Journal of Antibiotics, 1982